CD4 and neoplasm: Efficient tumor cell killing was maintained with either CD4+ (Ad‐CIITA: 75.6% ± 16.8) or CD8+ T‐cells (Ad‐CIITA: 67.5% ± 28.8) (Fig. 4C).